540729 — Vanta Bioscience Income Statement
0.000.00%
Last trade - 00:00
- IN₹403.97m
- IN₹996.97m
- IN₹62.76m
C2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | PRESS | ARS |
Standards: | IAS | IAS | IAS | — | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 124 | 141 | 100 | 96.9 | 62.8 |
Cost of Revenue | |||||
Gross Profit | 111 | 130 | 92.2 | 89.9 | 53.3 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 98.4 | 110 | 72.9 | 75.4 | 113 |
Operating Profit | 25.9 | 31.8 | 27.5 | 21.5 | -50.6 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 11 | 13.4 | 5.89 | 2.28 | -103 |
Provision for Income Taxes | |||||
Net Income After Taxes | 6.98 | 10.1 | 4.48 | 0.882 | -104 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 6.96 | 10 | 4.5 | 0.882 | -64.8 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 6.96 | 10 | 4.5 | 0.882 | -64.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.54 | 1.59 | 0.686 | 0.14 | -10.3 |